Importing peptides from China to the US

Key takeaways
US admissibility depends on the material and its actual intended use, not a research statement alone.
Verify the manufacturing site and lot-specific analytical evidence before committing to a supplier.
Match shipping conditions to product stability data and allow for customs holds.
A COA, an SDS and GMP evidence serve different purposes and do not replace entry requirements.
Importing research peptides from China to the US starts with determining what the material is, how the receiving organization will use it and which requirements apply. A shipment for a laboratory experiment can follow a different regulatory path from a drug ingredient or a product intended for administration to people. Supplier paperwork and a shipping label cannot settle that distinction on their own.
For procurement and laboratory teams, the practical sequence is to establish admissibility, qualify the source, assemble consistent documentation and then select a transport plan that protects the material through delivery.
Can you legally import peptides from China?
Some imports are permissible, but there is no blanket approval covering all Chinese research peptides. The peptide's identity, intended use and regulatory status matter. FDA's human drug import guidance explains that its drug definition includes relevant active pharmaceutical ingredients and that applicable drug requirements are verified at importation.
A statement that material is for laboratory work does not override evidence that it is being marketed or supplied for human use. Keep the purchase order, product description, end-use statement and actual laboratory activity consistent. Mercury's separate research use only (RUO) guide explains the labeling distinction.
Before importing peptides to the US, have the importer and qualified regulatory adviser determine whether the product falls within FDA jurisdiction, whether an investigational or other lawful pathway is relevant and whether other chemical or biological controls apply. FDA's Import Alert 66-41 describes detention risks for unapproved new drugs. A past successful delivery does not establish that a later shipment is admissible.
Qualify the manufacturing source before placing an order
Where are peptides manufactured? Synthesis, purification, analytical testing and final packaging can occur at different facilities, sometimes in different countries. A seller's address does not establish the manufacturing origin. Ask which legal entity performs each operation and which site releases the batch.
When comparing Chinese peptide suppliers, distinguish the actual manufacturer from a distributor or broker. A China-based peptide supplier should be able to identify the production site, explain subcontracted work and provide traceability from the lot shipped to the analytical records. Check certificates with their issuer and confirm that their scope covers the relevant site and activity.
Read the COA as evidence about a specific lot
A certificate of analysis should identify the peptide, lot number, applicable specification, methods, results and approval. Review sequence or identity evidence, chromatographic purity and any additional attributes required by the research protocol. Purity alone does not demonstrate the quantity of peptide present, sterility, suitability for human use or freedom from every relevant impurity.
Ask peptide manufacturers in China for underlying analytical records when the work warrants them. An independently tested sample may help a supplier-qualification program, but testing a sample does not establish the quality of every subsequent lot. Define how lot changes, substitutions and out-of-specification findings will be handled.
Match GMP evidence to the intended application
GMP documentation can matter when the peptide is a drug substance or enters a regulated manufacturing process. It is not a universal import certificate for every research chemical. Verify the applicable manufacturing standard, inspection history and quality agreement rather than relying on a generic “GMP certified” statement. Do not describe FDA establishment registration as product approval.
Build a consistent import document set
Different documents answer different questions. The following checks help separate technical evidence from customs and regulatory filings.
Document or record | What to verify | Important boundary |
|---|---|---|
Commercial invoice | Accurate identity, quantity, value, origin, parties and intended use | Free samples still need an appropriate customs value |
Lot-specific COA | Lot match, methods, specifications and reported results | Does not establish admissibility or clinical suitability |
Safety data sheet (SDS), where applicable | Current product composition, hazards and transport information | Supports hazard review rather than replacing classification |
Manufacturing and quality records | Actual sites, traceability and GMP evidence where relevant | Requirements depend on product status and use |
Entry and agency information | Importer details, tariff classification and applicable FDA or other filings | Must reflect the real product, not a convenient generic description |
The importer and broker should review the complete set before pickup. Mercury's commercial invoice guide covers invoice construction, while its customs brokerage services address entry coordination.
Ship to the peptide's stability requirements
Lyophilization does not create one standard shipping temperature for all peptides. Obtain the supplier's supported transport conditions for the exact material, including allowable time, temperature, moisture protection and any restrictions on repeated warming. Frozen storage instructions alone may not establish what is acceptable during transit.
For bulk peptides from China, evaluate the full packout rather than simply adding more coolant. Payload mass, vial arrangement, insulation, refrigerant conditioning and seasonal exposure can change thermal performance. Use a qualified configuration that covers the planned route plus a realistic delay allowance. If dry ice is used, its separate air transport requirements also apply.
Coordinate export readiness, destination clearance and a receiving appointment. Avoid dispatching a temperature-sensitive shipment toward a closed laboratory or a holiday backlog without a documented holding arrangement. A logger provides evidence of conditions, while an active response plan determines who can intervene if the shipment stalls.
Why peptide shipments are held at customs
Common review triggers include vague descriptions, inconsistent end-use claims, incorrect value or origin information, missing agency data and concerns about the manufacturer or product. A COA cannot resolve an inaccurate entry by itself. If FDA detains a shipment, follow the notice and response process with the responsible importer rather than assuming that a replacement label will secure release.
Before release from the supplier, assign responsibility for these tasks:
Confirm the product's regulatory route and check relevant restrictions or import alerts.
Approve the source, lot documents and exact material description.
Have the broker review entry data and any required agency information.
Confirm carrier acceptance, packaging duration and an authorized delay response.
Arrange receipt, inspection and review of condition records before laboratory use.
For teams asking how to import peptides from China or how to order peptides from China, these checks belong before payment and dispatch. A decision to buy peptides from China should follow the receiving institution's procurement and regulatory controls. Successful sourcing ends with documented receipt of the right material in acceptable condition, with its identity, lot history and import records intact.



